Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	4,338	3,953	-535.6	3,620	3,322	2,342
Depreciation & Amortization	217.3	209.8	207.2	181.3	148.3	125.6
Stock-Based Compensation	686.2	685.9	698.5	581.2	491.3	441.4
Other Adjustments	-292.9	-18.4	-347.9	-579.1	-172.5	-160.4
Change in Receivables	-137.9	-347.3	-99.3	-84.1	-358.6	-274.7
Changes in Inventories	-454.8	-524.2	-517.3	-322.9	-136.4	-92.8
Changes in Accounts Payable	46.2	36.8	49.5	48.7	120.8	31.9
Changes in Accrued Expenses	-94.5	-116.9	212.9	429.4	542.5	305.4
Changes in Other Operating Activities	-44.9	-247.5	-160.6	-336.8	172.5	-75
Operating Cash Flow	4,241	3,631	-492.6	3,537	4,130	2,644
Operating Cash Flow Growth	-	-	-	-14.35%	56.23%	-18.75%
Capital Expenditures	-530.3	-437.6	-297.7	-200.4	-204.7	-235
Purchases of Intangible Assets	-	-	-187.7	-58	-	-
Purchases of Investments	-7,257	-6,397	-7,696	-3,787	-988.6	-605.2
Proceeds from Sale of Investments	6,469	5,897	4,482	934.2	920	499.3
Payments for Business Acquisitions	-	-	-	-	-47.8	-
Other Investing Activities	-19.4	-24.7	-54	-31	-	-
Investing Cash Flow	-1,322	-945.4	-3,770	-3,142	-321.1	-340.9
Long-Term Debt Issued	-	-	-	-	-	28.3
Long-Term Debt Repaid	-4.1	-5.4	-33.6	-44.9	-85.5	-47
Net Long-Term Debt Issued (Repaid)	-4.1	-5.4	-33.6	-44.9	-85.5	-18.7
Issuance of Common Stock	138	127.7	114.6	134.6	186.3	102
Repurchase of Common Stock	-2,256	-2,387	-1,582	-653.7	-172	-1,561
Net Common Stock Issued (Repurchased)	-2,118	-2,260	-1,468	-519.1	14.3	-1,459
Other Financing Activities	2.5	3.7	6.2	1.8	3.5	-
Financing Cash Flow	-2,120	-2,261	-1,495	-562.2	-67.7	-1,478
Effect of Exchange Rate Changes on Cash and Cash Equivalents	20.1	90.9	-42.6	26.9	-29.2	-13.4
Net Cash Flow	819.5	515.6	-5,800	-139.7	3,712	811.2
Free Cash Flow	3,710	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Growth	16.17%	-	-	-14.99%	62.97%	-19.55%
FCF Margin	30.37%	26.61%	-7.17%	33.81%	43.95%	31.80%
Free Cash Flow Per Share	14.42	12.38	-3.06	12.81	15.15	9.27
Levered Free Cash Flow	3,473	2,868	-1,075	3,374	3,880	2,384
Unlevered Free Cash Flow	3,070	2,474	-4.02	2,966	4,024	2,447

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q